Breaking Finance News

JPMorgan Chase & Co. downgraded Patheon NV (NASDAQ:PTHN) to Neutral in a report released today.

Just yesterday Patheon NV (NASDAQ:PTHN) traded 0.00% even at $34.81. Patheon NV’s 50-day moving average is $34.98 and its 200-day moving average is $34.98. The last stock price is down 0.00% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.03% over the same time period. 229,751 shares of PTHN traded hands, up from an average trading volume of 0

JPMorgan Chase & Co. has downgraded Patheon NV (NASDAQ:PTHN) to Neutral in a report released on 6/08/2017.

Previously on 5/19/2017, Zacks Investment Research released a statement about Patheon NV (NASDAQ:PTHN) increased the target price from $0.00 to $39.00. At the time, this indicated a possible upside of 0.12%.

Recent Performance Chart


Patheon NV has 52 week low of $24.45 and a 52 week high of $35.02 with a PE ratio of 44.85 and has a market capitalization of $0.

Brief Synopsis On Patheon NV (NASDAQ:PTHN)

Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company's segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products. The PDS segment provides a range of formulation, production and technical services from the early stages of a product's development to regulatory approval, as well as for new formulations of approved products for lifecycle extension. The DSS segment provides small molecule active pharmaceutical ingredient (API) and outsourced manufacturing solutions for large molecule biological API from early development through commercial scale production. It provides an integrated range of API and finished drug product services to its customers, from formulation development to clinical and commercial-scale manufacturing.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.